ProQR Therapeutics (PRQR) Competitors

Pharming Group (NASDAQ:PHAR) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends, analyst recommendations and community ranking.

Do analysts rate PHAR or PRQR?

Pharming Group currently has a consensus price target of $30.00, suggesting a potential upside of 195.71%. ProQR Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 349.44%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
ProQR Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

Is PHAR or PRQR more profitable?

Pharming Group has a net margin of -6.09% compared to ProQR Therapeutics' net margin of -134.31%. Pharming Group's return on equity of -7.65% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	-6.09%	-7.65%	-3.82%
ProQR Therapeutics	-134.31%	-71.58%	-19.70%

Which has more risk and volatility, PHAR or PRQR?

Pharming Group has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.

Which has higher valuation & earnings, PHAR or PRQR?

Pharming Group has higher revenue and earnings than ProQR Therapeutics. Pharming Group is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$320.71M	2.15	-$10.55M	-$0.20	-50.73
ProQR Therapeutics	$18.97M	9.87	-$30.43M	-$0.35	-5.09

Does the media prefer PHAR or PRQR?

In the previous week, ProQR Therapeutics had 5 more articles in the media than Pharming Group. MarketBeat recorded 5 mentions for ProQR Therapeutics and 0 mentions for Pharming Group. ProQR Therapeutics' average media sentiment score of -0.01 beat Pharming Group's score of -0.21 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Pharming Group	Neutral
ProQR Therapeutics	Neutral

Does the MarketBeat Community favor PHAR or PRQR?

ProQR Therapeutics received 316 more outperform votes than Pharming Group when rated by MarketBeat users. However, 67.65% of users gave Pharming Group an outperform vote while only 62.20% of users gave ProQR Therapeutics an outperform vote.

Company	Underperform	Outperform
Pharming Group	Outperform Votes 23 67.65%	Underperform Votes 11 32.35%
ProQR Therapeutics	Outperform Votes 339 62.20%	Underperform Votes 206 37.80%

Do institutionals and insiders believe in PHAR or PRQR?

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

ProQR Therapeutics beats Pharming Group on 12 of the 19 factors compared between the two stocks.